Author:
Banchs Javier E.,Wolbrette Deborah L.,Samii Soraya M.,Penny-Peterson Erica D.,Patel Parag P.,Young Sallie K.,Gonzalez Mario D.,Naccarelli Gerald V.
Publisher
Springer Science and Business Media LLC
Subject
Physiology (medical),Cardiology and Cardiovascular Medicine
Reference21 articles.
1. Fuster, V., Ryden, L. E., Cannom, D. S., et al. (2006). ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American college of cardiology/American heart association task force on practice guidelines and the European society of cardiology committee for practice guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). Circulation, 114, e257–e354.
2. Gwilt, M., Arrowsmith, J. E., Blackburn, K. J., et al. (1991). UK-68,798: a novel, potent and highly selective class III antiarrhythmic agent which blocks potassium channels in cardiac cells. The Journal of Pharmacology and Experimental Therapeutics, 256, 318–324.
3. Mounsey, J. P., & DiMarco, J. P. (2000). Cardiovascular drugs. Dofetilide. Circulation, 102, 2665–2670.
4. Roukoz, H., & Saliba, W. (2007). Dofetilide: a new class III antiarrhythmic agent. Expert Review of Cardiovascular Therapy, 5(1), 9–19.
5. Greenbaum, R. A. (1999). Meeting highlights: highlights of the 71st Scientific Sessions of the American Heart Association. The EMERALD trial. Circulation, 99, 2486–2491.
Cited by
21 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献